Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial

R. Bruna, F. Benedetti, C. Boccomini, C. Patti, A.M. Barbui, A. Pulsoni, M. Musso, A.M. Liberati, G. Gini, C. Castellino, F. Rossini, F. Ciceri, D. Rota-Scalabrini, C. Stelitano, F. Di Raimondo, A. Tucci, L. Devizzi, V. Zoli, F. Zallio, F. NarniA. Dondi, G. Parvis, G. Semenzato, F. Lanza, T. Perrone, F. Angrilli, A. Billio, A. Gueli, B. Mantoan, A. Rambaldi, A. Massimo Gianni, P. Corradini, R. Passera, M. Ladetto, C. Tarella

Research output: Contribution to journalArticle

Abstract

Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular lymphoma patients aged
Original languageEnglish
Pages (from-to)2241-2248
Number of pages8
JournalHaematologica
Volume104
Issue number11
DOIs
Publication statusPublished - 2019

    Fingerprint

Keywords

  • cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine
  • immunoglobulin
  • lactate dehydrogenase
  • rituximab
  • acute leukemia
  • adult
  • anaphylaxis
  • Article
  • autograft
  • autologous hematopoietic stem cell transplantation
  • cancer growth
  • cancer immunotherapy
  • cancer staging
  • cancer survival
  • controlled study
  • disease exacerbation
  • disease free survival
  • female
  • follicular lymphoma
  • Follicular Lymphoma International Prognostic Index
  • follow up
  • human
  • male
  • middle aged
  • minimal residual disease
  • multicenter study
  • myelodysplastic syndrome
  • overall survival
  • polymerase chain reaction
  • prospective study
  • randomized controlled trial
  • remission
  • sudden death

Cite this

Bruna, R., Benedetti, F., Boccomini, C., Patti, C., Barbui, A. M., Pulsoni, A., Musso, M., Liberati, A. M., Gini, G., Castellino, C., Rossini, F., Ciceri, F., Rota-Scalabrini, D., Stelitano, C., Di Raimondo, F., Tucci, A., Devizzi, L., Zoli, V., Zallio, F., ... Tarella, C. (2019). Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. Haematologica, 104(11), 2241-2248. https://doi.org/10.3324/haematol.2018.209932